Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials
The findings showed 44% of participants attained undetectable viral levels and normalisation of alanine aminotransferase at week 48.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance